The idea is that companies that are bulk manufacturing drugs need closer oversight than smaller compounding pharmacies that are merely customizing drugs for individual patients
Right alongside statins and antihypertensives
Quick comparison: Peak owns cash-pay price, Ro owns insurance and FDA-approved catalog, and your coverage status decides the rest
A structured roadmap for clinical translation From a translational perspective, microbiome-based stratification cannot be recommended as a routine clinical tool due to limited human evidence, methodological heterogeneity, absence of standardized analytical pipelines, and lack of validated microbial cut-offs
After treatments, cells were washed three times with PBS, and incubated with 1 mM NMM for 510 min
Here is how those pieces fit together as of April 2026, reported as published rather than promised